ArticleColloids and surfaces. B, Biointerfaces2016
PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer.
Article in Colloids and surfaces. B, Biointerfaces, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 127 citations in OpenAlex.
- Article
- Green PEGylated-Sily@ZnFe2O4 nanocomposites for amelioration of ROS and DNA damage in rat liver.Scientific reports · 2025Article
- Potential application of nanodelivery systems targeting ELAVL1 in prostate cancer treatment.Frontiers in oncology · 2025Review
- Metal Oxide Nanoparticles as Efficient Nanocarriers for Targeted Cancer Therapy: Addressing Chemotherapy-Induced Disabilities.Cancers · 2024Review
- Application of HInternational journal of molecular sciences · 2024Article
- Co-delivery of Siape1 and Melatonin byRecent patents on anti-cancer drug discovery · 2024Article
- Biomolecule-functionalized nanoformulations for prostate cancer theranostics.Journal of advanced research · 2023Review
- Nanomedicine in cancer therapy.Signal transduction and targeted therapy · 2023Review
- Nanoparticles-induced potential toxicity on human health: Applications, toxicity mechanisms, and evaluation models.MedComm · 2023Review
- Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy.Frontiers in immunology · 2023Review
- Indocyanine Green-based Glow Nanoparticles Probe for Cancer Imaging.Nanotheranostics · 2023Article
- Nanotherapeutic Approach to Delivery of Chemo- and Gene Therapy for Organ-Confined and Advanced Castration-Resistant Prostate Cancer.Critical reviews in therapeutic drug carrier systems · 2023Article
- Brief review: Applications of nanocomposite in electrochemical sensor and drugs delivery.Frontiers in chemistry · 2023Review
- Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer.Drug delivery · 2022Article
- Glu-Urea-Lys Scaffold Functionalized Superparamagnetic Iron Oxide Nanoparticles Targeting PSMA for In Vivo Molecular MRI of Prostate Cancer.Pharmaceutics · 2022Article
- Emerging trends in the nanomedicine applications of functionalized magnetic nanoparticles as novel therapies for acute and chronic diseases.Journal of nanobiotechnology · 2022Review
- Article
- Targeted Delivery Methods for Anticancer Drugs.Cancers · 2022Review
- Functionalized nanoparticles targeting biomarkers for prostate cancer imaging and therapy.American journal of clinical and experimental urology · 2022Review
- Systematic Identification of Genomic Markers for Guiding Iron Oxide Nanoparticles in Cervical Cancer Based on Translational Bioinformatics.International journal of nanomedicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
Docetaxel (Dtxl) is currently the most common therapeutic option for prostate cancer (PC). However, adverse side effects and problems associated with chemo-resistance limit its therapeutic outcome in clinical settings. A targeted nanoparticle system to improve its delivery to and activity at the tumor site could be an attractive strategy for PC therapy. Therefore, the objective of this study was to develop and determine the anti-cancer efficacy of a novel docetaxel loaded, prostate specific membrane antigen (PSMA) targeted superparamagnetic iron oxide nanoparticle (SPION) (J591-SPION-Dtxl) formulation for PC therapy. Our results showed the SPION-Dtxl formulation exhibits an optimal particle size and zeta potential, which can efficiently be internalized in PC cells. SPION-Dtxl exhibited potent anti-cancer efficacy via induction of the expression of apoptosis associated proteins, downregulation of anti-apoptotic proteins, and inhibition of chemo-resistance associated protein in PC cell lines. J591-SPION-Dtxl exhibited a profound uptake in C4-2 (PSMA(+)) cells compared to PC-3 (PSMA(-)) cells. A similar targeting potential was observed in ex-vivo studies in C4-2 tumors but not in PC-3 tumors, suggesting its tumor specific targeting. Overall, this study suggests that a PSMA antibody functionalized SPION-Dtxl formulation can be highly useful for targeted PC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.